Skip to main content

Advertisement

SpringerLink
Log in

Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

In some situations, there is a need for rapid mutation tests for guiding clinical decisions and starting targeted therapies with minimal delays. In this study we evaluated the turnaround time before and after the implementation of a fully automated multiplex assay for KRAS and NRAS/BRAF mutation tests (Idylla™ platform, Biocartis) in metastatic colorectal cancer. The objective of this project was to compare the turnaround times in 2017–2018 with the fully automated multiplex assay to the 2016 results with previous methods. Centers with a number of tests for metastatic colorectal cancer > 100 yearly and a usual turnaround time ≥ 3 weeks for mutation detection were selected. Results of 505 KRAS tests and 369 NRAS/BRAF tests were transmitted by 10 centers. The mean turnaround time from test prescription to reception of results was reduced from 25.8 days in 2016 to 4.5 days in 2017–2018. In conclusion, this pilot project shows that the Idylla™ platform for testing KRAS and NRAS/BRAF mutations allows an optimized turnaround time from test prescription to reception of results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T (2015) Colorectal cancer. Nat Rev Dis Primers 1:15065

    Article  Google Scholar 

  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403

    Article  CAS  Google Scholar 

  3. Hocking CM, Price TJ (2014) Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therap Adv Gastroenterol 7:20–37

    Article  CAS  Google Scholar 

  4. Prenen H, Tejpar S, Van Cutsem E (2010) New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 16:2921–2926

    Article  CAS  Google Scholar 

  5. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308–1324

    Article  CAS  Google Scholar 

  6. Er TK, Chen CC, Bujanda L, Herreros-Villanueva M (2014) Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. Biomed Res Int 2014:591867

    Article  Google Scholar 

  7. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  CAS  Google Scholar 

  8. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  CAS  Google Scholar 

  9. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034

    Article  CAS  Google Scholar 

  10. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R (2015) Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev 41:653–659

    Article  CAS  Google Scholar 

  11. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26:13–21

    Article  CAS  Google Scholar 

  12. Zenonos K, Kyprianou K (2013) RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol 5:97–101

    Article  Google Scholar 

  13. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459–465

    Article  CAS  Google Scholar 

  14. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6:479–507

    Article  CAS  Google Scholar 

  15. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934

    Article  CAS  Google Scholar 

  16. Oikonomou E, Koustas E, Goulielmaki M, Pintzas A (2014) BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 5:11752–11777

    Article  Google Scholar 

  17. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–i9

    Google Scholar 

  18. Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, Van Cutsem E (2011) Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 6:133–145

    Article  Google Scholar 

  19. Institut National du Cancer. Accès aux tests moléculaires EGFR, RAS et BRAF. Résultats d’une enquête dans 5 régions françaises. Janvier 2016

  20. de Biase D, de Luca C, Gragnano G, Visani M, Bellevicine C, Malapelle U, Tallini G, Troncone G (2016) Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. J Clin Pathol

  21. Solassol J, Vendrell J, Markl B, Haas C, Bellosillo B, Montagut C, Smith M, O’Sullivan B, D’Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pages JC, Sillekens P (2016) Multi-Center Evaluation of the Fully Automated PCR-Based Idylla KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PLoS One 11:e0163444

    Article  Google Scholar 

  22. Johnston L, Power M, Sloan P, Long A, Silmon A, Chaffey B, Lisgo AJ, Little L, Vercauteren E, Steiniche T, Meyer T, Simpson J (2018) Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. J Clin Pathol 71:336–343

    Article  CAS  Google Scholar 

  23. Scott RJ, Fox SB, Desai J, Grieu F, Amanuel B, Garrett K, Harraway J, Cheetham G, Pattle N, Haddad A, Byron K, Rudzki B, Waring P, Iacopetta B (2014) KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at? Asia Pac J Clin Oncol 10:261–265

    Article  Google Scholar 

  24. INCa (Bonnes pratiques pour la recherche à visée théranostique demutations somatiques dans les tumeurs solides. Août 2010) https://www.e-cancer.fr/content/download/63175/568709/file/OUTTHERANOS10.pdf

  25. INCa. Plan Cancer 2014–2019 https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Plan-Cancer-2014-2019

Download references

Funding

Amgen France.

Author information

Authors and Affiliations

  1. Medipath, Aix-Marseille, Éguilles, France

    Stéphane Rossat

  2. Saint-Joseph Hospital, Marseille, France

    Hervé Perrier

  3. Institute Montsouris, Paris, France

    Marine Lefevre & Christophe Louvet

  4. Ouest Pathologie, Rennes, France

    Nathalie Le Berre

  5. Private Hospital St Grégoire, Saint-Grégoire, France

    Jérôme Chamois

  6. Alizés Pathology Center, Baie-Mahault, Guadeloupe, France

    Maryline Dorel

  7. Les Eaux Claires Clinic, Baie-Malhault, Guadeloupe, France

    Daniel Vacque

  8. Limoges Polyclinic, Limoges, France

    Angélique Guillaudeau

  9. Chénieux Clinic, Limoges, France

    Dominique Genet

  10. Pathologie Center MAILLET Evelyne, Ste Clotilde, La Réunion, France

    Evelyne Maillet

  11. AMGEN France, Boulogne-Billancourt, France

    Simon Triby

  12. Rouen University Hospital, Rouen, France

    Jean-Christophe Sabourin

  13. Hôpital Charles Nicolle, Service de Pathologie, 1 rue de Germont, 76031, Rouen Cedex, France

    Jean-Christophe Sabourin

Authors
  1. Stéphane Rossat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hervé Perrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marine Lefevre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christophe Louvet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nathalie Le Berre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jérôme Chamois
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maryline Dorel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel Vacque
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Angélique Guillaudeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dominique Genet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Evelyne Maillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Simon Triby
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jean-Christophe Sabourin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Christophe Sabourin.

Ethics declarations

Conflict of Interest

Stéphane ROSSAT: No conflict of interest.

Hervé PERRIER : Amgen, Roche, Servier, Sanofi

Marine LEFEVRE: No conflict of interest

Christophe LOUVET: MSD, Roche, Halozyme, Servier, AstraZeneca

Nathalie LE BERRE: No conflict of interest

Jérôme CHAMOIS : Astellas, Ipsen, Janssen, Sanofi Aventis

Maryline DOREL: No conflict of interest

Daniel VAQUE: Amgen, Roche, Janssen

Angélique GUILLAUDEAU: No conflict of interest

Dominique GENET: Novartis, Pfizer, Roche

Evelyne MAILLET: No conflict of interest

Simon TRIBY: Amgen employee

Jean-Christophe SABOURIN: Amgen, Merck Serono, Pfizer, Bayer, BMS, MSD, AstraZeneca, Boehringer Ingelheim

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rossat, S., Perrier, H., Lefevre, M. et al. Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions. Pathol. Oncol. Res. 26, 2469–2473 (2020). https://doi.org/10.1007/s12253-020-00818-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-020-00818-y

Keywords

Search

Navigation